Skip to Content
Morningstar

Lonza Group Ltd LONN

Morningstar Rating
Unlock
Stock XSWX Rating as of
CHF 504.80 +2.60 (0.52%)
View Full Chart
As of Delayed Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Price vs Fair Value

View History
LONN is trading at a 499% premium.
Price
CHF 502.20
Fair Value
CHF 646.00
Uncertainty
Medium
1-Star Price
CHF 888.20
5-Star Price
CHF 897.00
Economic Moat
Vsmjly
Capital Allocation
Ljrkdhkg

Bulls Say, Bears Say

Bulls

The pharma biotech and nutrition segment is a sticky business with long-term contracts and high switching costs for its customers.

Bears

Lonza is vulnerable to facility closures whether from natural disasters or manufacturing issues, as a warning letter from the FDA can result in manufacturing delays or closures.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LONN is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
CHF 502.20
Day Range
CHF 503.40–507.20
52-Week Range
CHF 308.60–559.40
Bid/Ask
CHF 504.60 / CHF 505.00
Market Cap
CHF 36.39 Bil
Volume/Avg
9,122 / 180,864

Key Statistics

Price/Earnings (Normalized)
31.31
Price/Sales
5.51
Dividend Yield (Trailing)
0.80%
Dividend Yield (Forward)
0.80%
Total Yield
3.59%

Company Profile

Lonza Group ltd is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Large Growth
Total Number of Employees
18,000
Website
https://www.lonza.com

Competitors

Valuation

View More
Metric
LONN
CTLT
02269
Price/Earnings (Normalized)
 31.3199.6012.12
Price/Book Value
 3.832.841.15
Price/Sales
 5.512.492.58
Price/Cash Flow
 27.8042.268.22
Price/Earnings
LONN
CTLT
02269

Financial Strength

Metric
LONN
CTLT
02269
Quick Ratio
 1.121.562.35
Current Ratio
 1.772.512.78
Interest Coverage
 9.00−4.0725.95
Quick Ratio
LONN
CTLT
02269

Profitability

Metric
LONN
CTLT
02269
Return on Assets (Normalized)
 5.28%−3.09%8.91%
Return on Equity (Normalized)
 9.02%−7.79%13.28%
Return on Invested Capital (Normalized)
 7.29%−0.96%10.45%
Return on Assets
LONN
CTLT
02269
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
WsxxqnjvqMhwd$206.2 Bil
 Danaher Corp
DHR
NnskkhtdlYcspql$177.2 Bil
 IDEXX Laboratories Inc
IDXX
PxbhxwzrknJkhcf$40.1 Bil
 IQVIA Holdings Inc
IQV
VvzxxyfgXdwrd$37.9 Bil
 Agilent Technologies Inc
A
PwpgtkdxxMxr$36.9 Bil
 Mettler-Toledo International Inc
MTD
GjvwnpgnnGyxvzps$28.7 Bil
 Icon PLC
ICLR
TzqktbfqGcdfvjn$26.6 Bil
 Illumina Inc
ILMN
DnytgtsLrvjppt$17.3 Bil
 Labcorp Holdings Inc
LH
SjzxpnjdJvwrqv$17.2 Bil
 Waters Corp
WAT
CkgjqthyrBld$17.0 Bil

Sponsor Center